Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Health literacy and natural alternatives are two areas where Haleon's EMEA and LATAM head Filippo Lanzi sees potential for growth, in addition to Rx-to-OTC switch, he tells HBW Insight in an exclusive interview. Lanzi also digs deeper into Haleon's recently published first-half sales and earnings results and shares his thoughts on how the firm will meet the multiple challenges posed by the current social and economic environment.
The Honest Company alum brings to the Independent Beauty Association an extensive R&D background and the conviction that constraints on businesses today can and should foster innovation. That said, unduly burdensome legislation threatens to have a stifling effect on cosmetics innovation, the group’s new president and CEO tells HBW Insight in Part 2 of this interview.
Joining IBA from The Honest Company, where he headed up innovation, Frey aims to promote networking and collaboration within the group’s membership in an environment where in-person events – and travel budgets – still have not returned to pre-pandemic levels. Frey spoke with HBW Insight about his career to date and his goals for IBA in the near and longer terms.
In this episode, HBW Insight talks to Haleon’s global head of regulatory intelligence and policy, Ian Urquhart, about the innovative and flexible approaches that regulators took to ensuring access to medicines during the coronavirus pandemic. Urquhart speaks about his work with the Global Self-Care Federation, where the regulatory affairs committee which he chairs has been looking into what happened during the pandemic and drawing lessons for the future. Strengthening supply chains, Rx-to-OTC switch and e-commerce are all on the agenda for the organization, which has published a series of papers in these areas to inform future self-care policy and regulation across the world.
HBW Insight chats with general manager of Novartis' German subsidiary 1A Pharma about the firm's exit from the country's children's fever category. An inflexible price system for reimbursable medicines and inflationary pressures all contributed to the decision, Michael Klein explains, which has left only two manufacturers supplying the OTC liquid paracetamol market.
In this episode, HBW Insight speaks to Elan Sudberg, CEO of Alkemist Labs and chair of the American Herbal Product Association’s Psychedelic Plants and Fungi committee. Sudberg talks about the founding of the committee and the regulatory hoops that companies will have to jump through to research and develop psychedelic supplements, as well as the benefits that psychedelic plants are thought to have on human health.
In recent interview, CEO Blake Cadwell talked about Soundly’s business model and outlook for hearing aid marketplace after FDA's pending publication of rule aiming to make the devices more accessible. Firm since June has offered online testing and advice for customers about hearing aids best suited for their needs.
In this episode, HBW Insight talks to regulatory expert Mihai Inceu about the challenges of innovating in Europe’s thriving food supplements market. Senior regulatory affairs officer at consultancy firm JensonR+, Inceu highlights some of the issues companies face in putting new wellness products onto the European market, particularly if they want to make health claims for herbal ingredients, also known as botanicals. As well as giving good advice about how to avoid getting into trouble with regulators, Inceu also points to some of the latest trends in this dynamic consumer health space.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.